Unknown

Dataset Information

0

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

ABSTRACT: This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to evaluate relationships between body mass index (BMI) and safety (major bleeding and all-cause mortality) and effectiveness [stroke/non-central nervous system (non-CNS) systemic embolism (SE)/myocardial infarction (MI)] outcomes in Japanese patients with non-valvular atrial fibrillation (NVAF) receiving rivaroxaban. Patients were categorized according to BMI (kg/m2) as underweight (

SUBMITTER: Murakawa Y 

PROVIDER: S-EPMC7332477 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

Murakawa Yuji Y   Ikeda Takanori T   Ogawa Satoshi S   Kitazono Takanari T   Nakagawara Jyoji J   Minematsu Kazuo K   Miyamoto Susumu S   Hayashi Yasuhiro Y   Kidani Yoko Y   Okayama Yutaka Y   Sunaya Toshiyuki T   Sato Shoichiro S   Yamanaka Satoshi S  

Heart and vessels 20200406 8

This sub-analysis of the XAPASS, a prospective, single-arm, observational study, aimed to evaluate relationships between body mass index (BMI) and safety (major bleeding and all-cause mortality) and effectiveness [stroke/non-central nervous system (non-CNS) systemic embolism (SE)/myocardial infarction (MI)] outcomes in Japanese patients with non-valvular atrial fibrillation (NVAF) receiving rivaroxaban. Patients were categorized according to BMI (kg/m<sup>2</sup>) as underweight (< 18.5), normal  ...[more]

Similar Datasets

Unknown Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
| S-EPMC6800859 | biostudies-literature
Unknown Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
| S-EPMC7026217 | biostudies-literature
Unknown Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
| S-EPMC6977317 | biostudies-literature
Unknown Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
| S-EPMC5129572 | biostudies-literature
Unknown Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
| S-EPMC5927458 | biostudies-literature
Unknown Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: A PRISMA-compliant article.
| S-EPMC8360482 | biostudies-literature
Unknown Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
| S-EPMC4941167 | biostudies-literature
Unknown Association between body mass index and the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran: a cohort study.
| S-EPMC7189264 | biostudies-literature
Unknown XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
| S-EPMC4823634 | biostudies-literature
Unknown Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
| S-EPMC4508487 | biostudies-literature